STING1 and breast cancer: recently demonstrated that combining PTT with dual STING agonists, MSA‐2 and Mn2+, could trigger robust systemic antitumor immunity in an orthotopic 4T1 murine breast cancer model (Figure 10).[114d] In this study, MSA‐2 was loaded into mesoporous polydopamine nanoparticles (MPDA) through π–π stacking interactions, after which dopamine was added to form a polydopamine coating.